Shaun Grady, Vice President of Strategic Partnering &amp, Business Development at AstraZeneca ... being launched and commercialised globally. Forxiga is now approved in Europe, and there ...

AstraZeneca is investing in the broadest and ... For example, by building on the success of Forxiga (dapagliflozin), the first SGLT2 inhibitor to demonstrate a mortality benefit in chronic kidney ...

Tens of thousands of people with chronic kidney disease in England could be eligible for treatment with AstraZeneca's SGLT2 inhibitor Forxiga, after NICE backed NHS use of the drug in draft ...

In substance and timing, AstraZeneca's decision to cancel a planned expansion of its flu vaccine facility at Speke is a blow to the government's recent zeal for growth. Instead of injecting £450m ...

AstraZeneca has cancelled plans for a £450m vaccine manufacturing plant in Liverpool, blaming a cut in funding from government. The investment, announced last year in the Tories' spring budget ...

The government has defended its negotiations with AstraZeneca, after the pharmaceutical giant ditched a planned £450m investment last week, blaming a shortfall in government funding. Science ...

UK drugmaker AstraZeneca overcame a drop in sales in China and the arrest of its top executive in the country to deliver an 18 per cent increase in revenues in the final quarter of 2024.

AstraZeneca has abandoned a £450m investment in a major UK vaccine plant just days after Rachel Reeves vowed to “kick-start economic growth”. The drugmaker, which is Britain’s most valuable ...

AstraZeneca has pulled out of plans to build a new £450m facility in Liverpool. AstraZeneca, which produced one of the Covid-19 jabs, has an existing site on Renaissance Way, Speke and during the ...

AstraZeneca has warned it could face a fine in China over possible unpaid import taxes, as it revealed strong sales of cancer drugs helped lift revenues higher. The FTSE 100-listed drugmaker said ...